NASDAQ · YMAB
Healthcare · Biotechnology
$8.61
Up+$0.02 (+0.23%)
Updated Oct 8, 2026, 9:42 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · YMAB
1M range · 0 trading sessions · Daily adjusted prices
YMAB does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning YMAB.
Company
Market Activity
Research & News
YMAB research
Company profile and research snapshot.
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2025 | HC Wainwright & Co. | Neutral | — |
| Aug 6, 2025 | Canaccord Genuity | Hold | — |
| Aug 5, 2025 | Jones Trading | Hold | — |
| May 29, 2025 | Oppenheimer | Outperform | — |
| May 19, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 16, 2025
SERB Pharmaceuticals has successfully acquired Y-mAbs Therapeutics for $8.60 per share, strengthening its rare oncology portfolio with the addition of Danyelza®, a treatment for pediatric neuroblastoma.
GlobeNewswire Inc. · Aug 26, 2025
Law firm Brodsky & Smith is investigating potential breaches of fiduciary duties by boards of several companies during recent merger and acquisition transactions, focusing on whether shareholders are receiving fair value.
The Motley Fool · Aug 8, 2025
Y-mAbs Therapeutics reported Q2 2025 results with revenue exceeding expectations but declining 14% year-over-year, primarily due to lower DANYELZA product sales. The company is being acquired by SERB Pharmaceuticals and is focusing on expanding its cancer therapy portfolio.
Benzinga · Aug 7, 2025
Law firm Monteverde & Associates is investigating the proposed sale of Y-mAbs Therapeutics to SERB Pharmaceuticals, where shareholders will receive $8.60 per share, to determine if the deal is fair.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning YMAB.
No results
No recent SID articles mention YMAB.
